| Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non–small-cell lung cancer GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of clinical oncology 34 (28), 3375, 2016 | 896 | 2016 |
| Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies ER Bleecker, DS Postma, RM Lawrance, DA Meyers, HJ Ambrose, ... The Lancet 370 (9605), 2118-2125, 2007 | 301 | 2007 |
| Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes … M Reck, M Schenker, KH Lee, M Provencio, M Nishio, K Lesniewski-Kmak, ... European journal of cancer 116, 137-147, 2019 | 201 | 2019 |
| Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12 … RF Storey, S Melissa Thornton, R Lawrance, S Husted, M Wickens, ... Platelets 20 (5), 341-348, 2009 | 87 | 2009 |
| AZD9291 in pre-treated T790M positive advanced NSCLC: AURA2 phase II study T Mitsudomi, CM Tsai, F Shepherd, L Bazhenova, JS Lee, GC Chang, ... Journal of Thoracic Oncology 10 (9), S320-S320, 2015 | 46 | 2015 |
| What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? R Lawrance, E Degtyarev, P Griffiths, P Trask, H Lau, D D’Alessio, ... Journal of Patient-Reported Outcomes 4 (1), 1-8, 2020 | 41 | 2020 |
| Classification of rheumatoid arthritis status with candidate gene and genome-wide single-nucleotide polymorphisms using random forests YV Sun, Z Cai, K Desai, R Lawrance, R Leff, A Jawaid, SLR Kardia, ... BMC proceedings 1, 1-6, 2007 | 40 | 2007 |
| 134O_PR: Plasma ctDNA analysis for detection of EGFR T790M mutation in patients (pts) with EGFR mutation-positive advanced non-small cell lung cancer (aNSCLC) S Jenkins, J Yang, S Ramalingam, K Yu, S Patel, S Weston, R Lawrance, ... Journal of Thoracic Oncology 11 (4), S153-S154, 2016 | 33 | 2016 |
| AZD9291 in pre-treated T790M positive advanced NSCLC: AURA study phase II extension cohort JCH Yang, MJ Ahn, SS Ramalingam, LV Sequist, S Novello, WC Su, ... Journal of Thoracic Oncology 10 (9), S319-S319, 2015 | 29 | 2015 |
| 135O_PR: Plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC GR Oxnard, KS Thress, RS Alden, R Lawrance, CP Paweletz, M Cantarini, ... Journal of Thoracic Oncology 11 (4), S154, 2016 | 23 | 2016 |
| Effect of β2-adrenergic receptor gene (ADRB2) 3′ untranslated region polymorphisms on inhaled corticosteroid/long-acting β2-adrenergic agonist response HJ Ambrose, RM Lawrance, CJ Cresswell, M Goldman, DA Meyers, ... Respiratory Research 13, 1-9, 2012 | 18 | 2012 |
| First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743 A Scherpereel, S Antonia, Y Bautista, F Grossi, D Kowalski, G Zalcman, ... Lung Cancer 167, 8-16, 2022 | 15 | 2022 |
| What matters most? Different stakeholder perspectives on estimands for an invented case study in COPD ON Keene, S Ruberg, A Schacht, M Akacha, R Lawrance, A Berglind, ... Pharmaceutical Statistics 19 (4), 370-387, 2020 | 15 | 2020 |
| Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced … J Chang, YL Wu, S Lu, J Wang, T Mok, L Zhang, J Feng, L Wu, HY Tu, ... Lung cancer 165, 71-81, 2022 | 12 | 2022 |
| Beta2-adrenergic receptor gene polymorphisms: is Arg/Arg genotype associated with serious adverse events during treatment with budesonide and formoterol in one pressurized … ER Bleecker, RM Lawrance, HJ Ambrose, M Goldman Am J Respir Crit Care Med 177, A775, 2008 | 9 | 2008 |
| Effect of polymorphisms in the beta2-adrenergic receptor gene (ADRB2) on response to long-acting beta2-agonist (LABA) therapy ER Bleecker, DS Postma, R Lawrance, DA Meyers, H Ambrose, ... Journal of Allergy and Clinical Immunology 119 (2), 524-525, 2007 | 9 | 2007 |
| First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year … M Reck, TE Ciuleanu, M Cobo, M Schenker, B Zurawski, J Menezes, ... European Journal of Cancer 183, 174-187, 2023 | 8 | 2023 |
| Beta2-adrenergic receptor Gly16Arg variation: effect on response to budesonide/formoterol (BUD/FM) or budesonide (BUD; post-formoterol) in children and adolescents with asthma ER Bleecker, R Lawrance, H Ambrose, M Goldman American Journal of Respiratory and Critical Care Medicine 177, 2008 | 5 | 2008 |
| Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial D Réa, C Boquimpani, MJ Mauro, Y Minami, A Allepuz, VK Maheshwari, ... Leukemia 37 (5), 1060-1067, 2023 | 4 | 2023 |
| OA05. 06 CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab+ Ipilimumab in High Tumor Mutational Burden Advanced NSCLC J Brahmer, M Schenker, KH Lee, M Provencio, M Nishio, ... Journal of Thoracic Oncology 13 (10), S332, 2018 | 4 | 2018 |
